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1 Introduction 
1.1 Chronic lymphocytic leukemia 
1.1.1 Definition and epidemiology 
Chronic lymphocytic leukemia (CLL) is a neoplastic disease characterized by the 
accumulation of small, mature-appearing lymphocytes in the blood, bone marrow and 
lymphoid tissues. CLL accounts for 30% of all leukemias and is the most common 
form of leukemia among older adults in Western countries (Goldin et.al 2007). 
The disease occurs at a median age of 65 to 70 years. Over the last years the 
number of younger patients under 60 years has increased, now representing about 
20% of all patients (Diehl et al. 1999, Dighiero et al. 1996). 
The overall median survival of patients with chronic lymphocytic leukemia (CLL) is 
about 10 years. The individual prognosis is, however, extremely variable. Whereas in 
some patients the disease runs an indolent clinical course and life expectancy is not 
shortened, in others the disease progresses rapidly, has aggressive behavior, and 
survival after diagnosis is inferior to 2-3 years. Considering its variable prognosis and 
the absence of a curative therapy, management of patients with CLL cannot be 
planned without taking into consideration their prognosis (Montserrat 2006). 
1.1.2 Pathogenesis 
CLL is characterized by the progressive accumulation of monoclonal peripheral 
(mature, but immune incompetent) B-cells in peripheral blood, lymphoid tissues, 
bone marrow, and spleen. The monoclonal population of B-cells in CLL expresses 
CD19, CD5, and CD23 on the surface (Chiorazzi et al. 2005). 
Chromosomal aberrations occurs in 82% of CLL cases, the most common is the 
deletion at 13q with 55% and it is associated with a long interval between diagnosis 
and the need for treatment (the treatment-free interval). The deletion at chromosome 
11q is at second place with 18 %, trisomy 12q follows with 16 %, whereas the 
deletion at 17p (7%) and 6q (6%) are rare.  
10-17 % of the CLL-patients have a mutation at the p53 gene, which regulates DNA 
repairing and apoptosis. These patients have a highly increased risk of progression, 
as the p53 mutation, mostly to be found in Binet stage C, is the strongest negative 
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prognostic factor for survival (Döhner et al. 2000). Moreover, the anti-apoptotic BCL2 
gene is reported to be over expressed in 65 to 70% of CLLs (Korz et al. 2002). 
1.1.3 Clinical symptoms 
CLL  symptoms usually develop slowly and most patients are asymptomatic at the 
time of presentation. They are diagnosed as the result of a routine blood test that 
shows a high leukocytes count. The cardinal clinical symptoms of CLL are 
splenomegaly, hepatomegaly, lymph nodes sweeling, leucocytosis, and in later 
stages because of the bone marrow supression anemia and thrombopenia. The B 
symptoms (fever, night sweat, weight loss), fatigue, malaise and infections are also 
possible to find. 
1.1.4 Diagnostic procedures 
A certain diagnosis of CLL is very important to make a differentiation between CLL 
and the other lymphoproliferative diseases, such as marginal cell lymphoma, hairy 
cell leukemia, mantle cell lymphoma, and follicular lymphoma. 
Following criteria are important for the diagnosis of CLL:  
• Peripheral blood 
Complete blood count shows lymphocytosis (lymphocyte count > 5000 
lymphocytes/µl) with an abundance of typical for CLL small but mature lymphocytes 
with small cytoplasm and a compact core with condensed chromatin but without 
nucleolus. Gumprecht shadow nuclei, which are cell detritus, can also possibly be 
found besides CLL cells. 
• Bone marrow examination 
A bone marrow aspirate and biopsy are generally not required to come to the 
diagnosis of CLL. But it is not to forget that basically CLL is a disease of the bone 
marrow, and it is therefore appropriate and recommended to evaluate the 
involvement of the bone marrow before starting therapy. The aspirate smear must 
show >30% of all nucleated cells to be lymphoid. A bone marrow examination also 
provides useful prognostic information by determining whether there is a diffuse or 
non diffuse involvement (Rozman et al. 1984), and permits an assessment of the 
erythroid precursors and megakaryocytes. 
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• Immunphenotype 
CLL may be confirmed by flow cytometry demonstrating the presence of CD5, CD19, 
CD20, CD23 and the restriction of light chains using antibodies against kappa or 
lambda light chains. 
1.1.5 Staging systems and prognostic factors 
The survival period from the time of diagnosis of CLL varies between 2 and more 
than 10 years, depending on stage (Hallek et al. 2005).  
We recognize that there are two somewhat different major staging methods that are 
currently in use throughout the world: the Rai system (Rai et al. 1975) and the Binet 
system (Binet et al. 1977, Cheson et al. 1996). They are used to estimate prognosis. 
Both are based on the extent of lymphadenopathy, splenomegaly, and hepatomegaly 
on physical exam and on the degree of anemia and thrombocytopenia in peripheral 
cell counts. These simple studies are inexpensive and can be applied to every 
patient without technical equipment (Hallek et al. 2005). 
In 1981, the IWCLL recommended that the two systems be integrated so that each of 
the Binet stages can be subclassified with the Rai stage. However, the IWCLL-
integrated system has not received widespread usage, and physicians continue to 
use either the Rai or Binet method in both patient care and in clinical trials (Cheson 
et al. 1996). However, the Rai and Binet staging systems lack the ability to 
distinguish prospectively patients with early stage CLL that will rapidly progress to 
aggressive disease from patients destined to remain in early stage for a long time 
(Keating et al. 2003). 
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The following tables describe the Rai staging sytem (Rai et al. 1975) and the Binet 
staging system (Binet et al. 1981)    
Table 1: Rai staging of CLL (Rai et al 1975) 
Stage Definition  Survival rate  
Low risk  > 10 years 
0 Absolute Lymphocytosis >15.000/µl  
 Bone marrow infiltration >40 %  
   
Intermediate risk  7 years 
I Absolute lymphocytosis with lymphadenopathy   
II Absolute lymphocytosis with either hepatomegaly or 
splenomegaly (with or without lymphadenopathy)  
 
   
High risk  2 – 3,5 years 
III Absolute lymphocytosis and anemia (Hb <11 g/dl) (with 
or without lymphadenopathy, hepatomegaly, or 
splenomegaly)  
 
IV Absolute lymphocytosis and thrombocytopenia 
(<100.000/mm3) with or without lymphadenopathy, 
hepatomegaly, splenomegaly, or anemia  
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Table 2: Binet staging of CLL (Binet et al 1981) 
Stage Definition  Survival rate  
Low risk  > 10 years 
A Hb >10 g/dl  
 Platelet count normal  
 Less than three areas of lymphoid enlargement*  
   
Intermediate risk  7 years 
B Hb >10 g/dl  
 Platelet count normal  
 Three or more areas of lymphoid enlargement*  
   
High risk  2 – 3,5 years 
C Hb <10 g/dl and/or Platelet count <100.000/mm3  
regardless of the number of areas of lymphoid 
enlargement*  
 
*Lymphoid areas include cervical, axillary, inguina l (>1cm) unilateral or bilateral, liver, and 
spleen. 
 
Both Rai’s stage 0 and Binet’s stage A consist of patients with a long survival, the 
median survival time exceeding 10 years. Binet’s stage A comprises 66% of CLL 
patients (all Rai’s stage 0, about 2/3 Rai’s stage I, 
1/3 Rai’s stage II, and 
1/5 Rai’s stage 
III) with a 78% 5-years survival rate, while Rai’s 0 comprises 31% of CLL patients 
with an 82.5% 5-years survival rate (FCGCLL 1990). 
The median survival rate of the low risk group (Binet A or Rai 0) is over 10 years, the 
intermediate risk group (Binet B, Rai I and II) is 5 until 7 years, and the high risk 
group (Binet C, Rai III and IV) is 2 until 3.5 years. Based on the observation, that 
patients are nowadays increasingly diagnosed at early stage, whose prognosis is 
relative inhomogenous, extra prognostic factors are necessary to make a distinction 
between indolent forms and quick progressive forms (Bergmann et al. 2008).  
Therefore, other parameters related to the genetics and biology of CLL, such as 
genomic aberrations and immunoglobulin variable heavy chain (IgVH) mutation 
status, are increasingly used for prediction of disease prognosis (Shanafelt et al. 
2004). 
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DNA microarray studies have shown that CLL cells with unmutated IgVH genes can 
be distinguished from those with mutated IgVH genes by the differential expression 
of a small number of genes, one of which encodes the 70-kDa zeta-associated 
protein (ZAP-70) (Rosenwald et al. 2001, Wiestner et al. 2003). 
Initially, CD38 expression also has been suggested as a surrogate marker for the two 
important IgVH mutated and unmutated subgroups of CLL (Damle et al. 1999). 
However, while a plethora of subsequent studies could clearly demonstrate the 
clinical value of CD38 as a prognostic marker with some degree of correlation to 
IgVH mutation status (Shanafelt et al. 2004), at present, both parameters are 
regarded as independent prognostic variables in CLL (Crespo et al. 2003, Hamblin et 
al. 2002). 
There are other parameters in order to predict the activity and the prognosis of 
chronic lymphocytic leukemia. In the following table we can see the whole prognostic 
parameters. 
Table 3: CLL Prognostic Parameters (Hallek et al 20 05) 
CLL Prognostic Parameters 
1. Aberrations in chromosomes 13(13q-), 11(11q-) and 
17(17p-) 
Döhner 2000,  Cheson et al. 
1996 
2. Cytoplasmic ZAP70 in CLL cells Moreton et al. 2005, 
Wendtner et al. 2004 
3. Expression of CD38 on CLL cells Bosch et al. 2002, Anaissie 
et al. 1998 
4. LDT (Lymphocyte Doubling Time) Montserrat et al. 1986, 
Plunkett et al. 1993 
5. Serum ß2-microglobulin concentration Rai et al. 2000 
6. Serum levels of soluble CD23 Johnson et al. 1996, 
Leporrier et al. 2001 
7. Serum thymidine kinase activity Hallek et al. 2004 
8. Somatic hypermutations of the immunoglobulin 
VH-gene region 
Bosch et al. 2002, O”Brien 
et al. 2001 
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While these parameters are potent in predicting the prognosis (survival, time to 
progression) of individual patients independent of the Binet or Rai stage, none of 
them has proven useful in predicting the need for therapy in CLL patients (Hallek et 
al. 2005). 
1.1.6 Treatment decision 
Evidence that current treatment can improve outcome is only available for patients 
with Rai III and IV or Binet B and C stages. Patients in earlier stages (Rai 0-II, Binet 
A) are generally not treated but monitored with a “watch and wait” strategy. In early 
stages, treatment is necessary only if symptoms associated with the disease occur 
(e.g., B symptoms, decreased performance status, or symptoms or complications 
from hepatomegaly, splenomegaly, and lymphadenopathy). (Hallek et al. 2005) 
Active disease should be clearly documented for protocol therapy and the following 
criteria must be met (Cheson 1996): 
1. A minimum of any one of the following disease-related symptoms must be 
present:  
a) Weight loss >10% within the previous 6 months  
b) Extreme fatigue (i.e. ECOG PS 2 or worse; cannot work or unable to perform 
usual activities) 
c) Fevers of greater than 100.5oF for >2 weeks without evidence of infection 
d) Night sweats without evidence of infection 
2. Evidence of progressive marrow failure as manifested by the development of, or 
worsening of, anemia and/or thrombocytopenia 
3. Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid 
therapy 
4. Massive (i.e. >6 cm below the left costal margin) or progressive splenomegaly 
5. Massive nodes or clusters (i.e. >10 cm in longest diameter) or progressive 
lymphadenopathy 
6. Progressive lymphocytosis with an increase of >50% over a 2-month period, or an 
anticipated doubling time of less than 6 months 
7. Marked hypogammaglobulinemia or the development of a monoclonal protein in 
the absence of any of the above criteria for active disease is not sufficient for 
protocol therapy. 
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In early-stage disease (Rai Stage 0 to II, Binet stage A), a group of patients with 
"smouldering CLL” can be identified. In 1998, Montserrat et al first proposed the 
“smouldering CLL” with the criteria needed to identify it (see table below). 
Table 4: Smouldering CLL; criteria 
Criteria for Smouldering CLL 
1. CLL Binet stage A 
2. Non-diffuse bone marrow histology 
3. Lymphocyte doubling time (LDT) > 12 months 
4. Hemoglobin level > 13 g/dl 
5. Absolute lymphocyte count < 30.000/ µl 
 
About one third of patients with Binet stage A have a “smouldering CLL” and they 
don’t need any therapy (Bergmann et al. 2008). “Smouldering CLL” is seen as the 
mild variant of the CLL Binet stage A with a survival rate equivalent to an age- and 
sex-matched normal population; this is of clinical relevance because patients with it 
require therefore no treatment unless progression takes place (Montserrat et al 1988, 
Cheson 1996, FCGCLL 1990). 
1.2 Study purpose 
The purpose of this thesis is to analyse the “watch and wait” CLL-1 patients that 
means not only the patients with low progression risk but also the high progression 
risk patients without any treatment. Based on the observation of the progression free 
survival and overall survival, the quality of the prognostic factors to prognose the 
survival time and the progression for CLL-1 patients in early stage will be evaluated. 
The following factors will be analysed in this study: B symptoms, ECOG performance 
status, alkaline phosphatase, serum glutamic oxaloacetic transaminase (SGOT), 
serum glutamate pyruvate transaminase (SGPT), gamma-glutamyltransferase 
(gamma-GT), cholinesterase (CHE), lactate dehydrogenase (LDH), blood urea 
nitrogen (BUN), uric acid, serum creatinine, total bilirubin, hepatomegaly, 
splenomegaly, lymphadenopathy. 
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2 Materials and method 
2.1 CLL-1 Protocol 
The CLL-patients with Binet stage A don’t actually need any therapy. But the 
progression of Binet stage A to a higher stage is associated with a reduction of the 
survival time (Molica et al. 1991, FCGCLL et al. 1990). The treatment with 
chlorambucil at an early stage induced a retardation of the progression, but not a 
prolongation of the survival time (FCGCLL et al. 1990, SCG PETHEMA et al. 1991, 
Shustik et al. 1988, Catovsky et al. 1988). Comparing to patients without any 
treatment it even appeared, that patients with an early treatment with chlorambucil 
showed a chemotherapy resistence and a high second carcinoma incidence 
(FCGCLL et al. 1990).  
In a randomized study, where a polychemotherapy combination of Cyclophosphamid, 
Doxorubicin, and Prednison (CAP) was tested against single therapy with 
Fludarabine, demonstrated that Fludarabine was better concerning the remission rate 
and the progression free survival (FCGCLL et al. 1996).  
Aim and study design  
This CLL-1-study is a multicenter, risk stratified trial evaluating the therapy and 
prognostic factors of CLL in Binet stage A patients. It consists of one group which 
includes all patients with low progression risk, and another group for all patients with 
high progression risk. The group consisting of high risk patients would then be 
divided into 2 cohorts after a phase III randomization (1:1) in order to compare the 
Fludarabine therapy with the standard option, which is observation without therapy 
(the so called “Watch and Wait” strategy). 
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Below is the flow sheet of the CLL-1-Study design 
Figure 1: CLL-1-Study design  
 
The following questions should be answered:  
1) Is it possible to extend the progression free survival and the overall survival of 
CLL patients in Binet A through an early, risk adapted Fludarabine therapy? 
2) How significant is the role of the new prognostic factors for CLL patients in 
Binet A? 
2.1.1.1 Protocol for risk-adapted therapy of CLL in  the Binet stage A 
Binet stage A patients are assessed in terms of their progression risk using clinical 
and biological prognostic factors:  bone marrow histology (infiltration type), 
lymphocyte doubling time (LDT), serum thymidine kinase, and the serum-ß2-
microglobulin.  
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A high progression risk is defined as:  
 
 
Not-nodular bone marrow infiltration or  LDT < 12 months 
 
and 
 
Serum Thymidine Kinase > 7.0 U/l or Serum-ß2-microglobulin > 3.5 mg/l. 
 
 
The patients with high progression risk would then after randomization either receive 
treatment with fludarabine in a controlled trial (cohort I) or only be observed (cohort 
II), whereas the patients without high progression risk according to the definition 
above (cohort III) would not be treated but observed until progression. 
2.1.1.1.1 Objectives 
• Primary objective 
o Progression free survival 
• Secondary objectives 
o Overall survival 
o Therapy efficacy (CR, PR, SD, progression (PD), remission duration) 
o Adverse events related to treatment (treatment safety) 
o Occurrence of infections 
o Quality of life 
 
2.1.1.2 Assessment of the significance of new progn ostic factors for CLL 
patients in Binet stage A 
The following parameter assessments are necessary at inclusion time to the study in 
order to analyse the prognostic factors: 
• Age 
• Gender 
• Binet-stage 
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• Rai-stage 
• Peripheral blood lymphocyte 
• Hemoglobin 
• Blood platelets 
• Bone marrow histology and cytology 
• Lymph node histology, when lymph node enlargement with at least 2 cm 
diameter exists and a punction (with small risk) is possible (including 
assessment of the histological subtype of CLL and CLL with plasmacellular 
differentiation) (Harris et al 1994) 
• Lymphocyte doubling time 
• Serum immunoglobulin level (IgA, IgM, IgG) 
• Serum-ß2-microglobulin 
• Serum thymidine kinase 
• Serum LDH 
• Serum albumin 
• Number of lymph node enlargements through clinical examination plus chest 
X-ray plus abdominal ultrasound 
• Hepatomegaly 
• Splenomegaly 
• Molecular cytogenetic with FISH method (e.g. p53-mutation, 11q-deletion)  
• B-symptoms 
• ECOG performance status 
2.1.1.2.1 Objectives 
• Primary objective 
o Progression free survival 
• Secondary objective 
o Overall survival 
2.2 Study population  
2.2.1 Inclusion Criteria  
1. Established diagnosis of B-CLL in Binet stage A. 
The diagnosis criteria for B-CLL are: 
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• Permanent (>3 months) absolute lymphocytosis >5000/µl in the 
peripheral        blood. 
• >30% mature lymphocytes in bone marrow. 
• Immunphenotype confirmation of the diagnosis in the form of low 
expression of surface immunoglobulin, CD5+, CD19+, CD20+, CD23+, 
inclusive CD5/CD19. (Matutes et al 1994, Rozman et al 1995) 
2. First diagnosis within 3 years before inclusion in study. 
3. No previous CLL therapy. 
4. Age between 18 and 75 years old. 
5. ECOG performance status 0-2. 
6. No insufficiency of important organ functions. 
7. Written informed consent of patient for participation in the study. 
8. Presence of all necessary parameters for risk stratification. 
9. Willingness to accept contraception if randomized to cohort I during the 
therapy. 
2.2.2 Exclusion Criteria  
1. Age under 18 years old and over 75 years old. 
2. ECOG performance status >2. 
3. Clinically apparent immune hemolysis. 
4. Positive Coombs test. 
5. Clinically apparent immune thrombocytopenia. 
6. Active secondary malignancy. 
7. Chemotherapy/radiotherapy for any neoplastic disease other than CLL prior to 
the study. 
8. HIV-infection. 
9. Pregnancy and/or nursing. 
10. Participation in another trial before and during the study. 
11. Concurrent severe diseases, as listed following: 
• Clinical apparent heart insufficiency 
• Cardiomyopathy 
• Myocardial infarction within the past 6 months prior to the study 
• Severe chronic obstructive lung disease with hypoxemia 
• Severe diabetes mellitus 
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• Hypertension difficult to control 
• Infection hard to control 
• Impaired liver function with serum bilirubin >2mg/dl and/or 
Transaminase over 3-times of ULN 
• Impaired renal function with creatinine >3 mg/dl 
• Clinically apparent cerebral dysfunction 
• Severe neurological or psychiatric diseases which hinder a good 
cooperation 
2.3 Procedure 
Patients stratified to the group with low progression risk (cohort III) and therefore 
counted among the control arm or patients randomized to the control arm of the 
study despite having high progression risk (cohort II) receive no chemotherapy, but 
would only be evaluated according to the „watch and wait“ strategy until the 
occurrence of progression, therapy indications and death. 
Progression occurs when at least one of the following criteria is met: 
• Progression to symptomatic stage Binet B or stage Binet C. 
• Progressive lymphocytosis with an increase of >100% (doubling) of the 
absolute lymphocyte count. 
• Transformation into a highly aggressive NHL (Richter-syndrome) or into 
Prolymphocytoid leukemia (>55% Prolymphocytes). 
• 25% size enlargement of liver and spleen or new evidence of previously not 
detected hepato/splenomegaly (confirmed by ultrasound examination). 
• Evidence of new lymph node enlargement (at least 1 cm diameter) in 2 
consecutive examinations with at least 2 weeks interval between them. 
• Clear lymph node enlargement, at least to the double (100%) of the previous 
size in 2 consecutive examinations with at least 2 weeks time in between. One 
of the lymph nodes must have at least 2 cm diameter. 
Indications for treatment due to progression/relapse are defined as following 
(Hellriegel 1997): 
• Progression to stage Binet C or symptomatic stage Binet B. 
• Progression with continuous increase of absolute lymphocyte count >100% 
and/or increase of leukocyte count >300.000/µl 
• Development of severe B-symptoms. 
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Patients included in the „watch and wait“arm (cohort II and III) would, in case of 
therapy indications, be included into the CLL4-Study (Fludarabine vs. combination of 
Fludarabine-Cyclophosphamide) if they are under 65 years old. Patients over 65 
years old would be included into CLL5-Study (Fludarabine vs. Chlorambucil). 
The follow-up evaluations are scheduled at months 3, 6, 9, 12, 18, 24 and annually 
thereafter.   
2.4 Statistic Analysis 
The analysis of the progression free survival and overall survival will be estimated 
using the Kaplan-Meier product-limit estimator. Log-rank test would also be used to 
analyze the survival curves. The level of significance (one sided test) is at 5 %. 
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3 Result 
3.1 Patients characteristics 
A total of 630 “watch and wait” patients were included in this study, which 95 patients 
had high progression risk (15.1%) and 535 patients had low progression risk (84.9%).  
3.2 Prognostic factors 
The progression free survival (PFS) and overall survival (OS) were evaluated using 
the Kaplan-Meier method and the survival chart using log ranks test (Kaplan & Meier 
1958). 
3.2.1 B symptoms 
Progression free survival  
538 patients were analysed, which 34 patients (6.3%) had B symptoms and 504 
patients (93.7%) did not have B symptoms.  
Table 5: Distribution of prognostic factor B sympto ms 
B symptoms Number of patients 
Yes 34 6.3% 
No 504 93.7% 
Total 538 100% 
 
23 patients (67.6%) of 34 patients with B symptoms had progression and 11 patients 
(32.4%) survived without progression. 280 patients (55.6%) of 504 patients without B 
symptoms had progression and 224 patients (44.4%) survived without progression. 
Table 6: Status of disease according to presence of  B symptoms 
B symptoms Progression Stable disease P value 
Yes 34 23 11 0.708 
100% 67.6% 32.4% 
No 504 280 224 
100% 55.6% 44.4% 
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The median progression free survival (PFS) for the group of the patients with B 
symptoms was 31.8 months, whereas for the group of the patients without B 
symptoms 49.0 months. This shows a difference of 17.2 months (p value 0.708).  
 
B symptoms  
Figure 2: B symptoms - Progression free survival in months                                   Yes  No 
                              
Overall survival  
542 patients were analysed, which 34 patients (6.3%) had B symptoms and 508 
patients (93.7%) did not have B symptoms.  
Table 7: Distribution of prognostic factor B sympto ms 
B symptoms Number of patients 
Yes 34 6.3% 
No 508 93.7% 
Total 542 100% 
 
7 patients (20.6%) of 34 patients with B symptoms died and 27 patients (79.4%) 
survived. 48 patients (9.4%) of 508 patients without B symptoms died and 460 
patients (90.6%) survived. 
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Table 8: Survival status according to presence of B  symptoms 
B symptoms Dead Alive P value 
Yes 34 7 27 0.198 
100% 20.6% 79.4% 
No 508 48 460 
100% 9.4% 90.6% 
 
After about 10 years evaluating time none of these two groups reached the median 
overall survival. If we compare the 75% percentile overall survival between these two 
groups, it shows a difference of 24.1 months (97.6 months for the group of the 
patients with B symptoms and 121.7 months for the group of the patients without B 
symptoms). 
B symptoms 
Figure 3: B symptoms - Overall survival in months                                       Yes  No 
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3.2.2 ECOG (Eastern Cooperative Oncology Group) per formance status 
Progression free survival  
527 patients were analysed, which 41 patients (7.8%) had ECOG performance status 
more than 0 and  486 patients (92.2%) had ECOG performance status equal  to 0.  
Table 9: Distribution of prognostic factor ECOG per formance status 
ECOG performance status Number of patients 
0 486 92.2% 
>0 41 7.8% 
Total 527 100% 
 
271 patients (55.8%) of 486 patients with ECOG performance status equal to 0 had 
progression and 215 patients (44.2%) survived without progression. 27 patients 
(65.9%) of 41 patients with ECOG performance status more than 0 had progression 
and 14 patients (34.1%) survived without progression. 
Table 10: Status of disease according to ECOG perfo rmance status 
ECOG performance status Progression Stable disease P value 
0 486 271 215 0.918 
100% 55.8% 44.2% 
>0 41 27 14 
100% 65.9% 34.1% 
 
The median progression free survival (PFS) for the group of the patients with ECOG 
performance status more than 0 was 40.3 months, whereas for the group of the 
patients with ECOG performance status equal to 0 51.8 months. This does not show 
a significant difference (p value 0.918).  
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ECOG performance status 
Figure 4: ECOG performance status - Progression free survival in months          0  >0 
 
Overall survival  
530 patients were analysed, which 489 patients (92.3%) had ECOG performance 
status equal to 0 and another 41 patients (7.7%) had ECOG performance status 
more than 0.  
Table 11: Distribution of prognostic factor ECOG pe rformance status 
ECOG performance status Number of patients 
0 489 92.3% 
>0 41 7.7% 
Total 530 100% 
 
8 patients (19.5%) of 41 patients with ECOG performance status more 0 died and 33 
patients (80.5%) survived. 46 patients (9.4%) of 489 patients with ECOG 
performance status equal to 0 died and 443 patients (90.6%) survived. 
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Table 12: Survival status according to ECOG perform ance status 
ECOG performance status Dead Alive P value 
>0 41 8 33 0.131 
100% 19.5% 80.5% 
0 489 46 443 
100% 9.4% 90.6% 
 
After about 10 years evaluating time none of these two groups reached the median 
overall survival. If we compare the 75% percentile overall survival between these two 
groups, it shows a difference of 42.6 months (79.1 months for the group of the 
patients with ECOG performance status more than 0 and 121.7 months for the group 
of the patients with ECOG performance status equal to 0). 
ECOG performance status 
Figure 5: ECOG performance status - Overall surviva l in months             0  >0 
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3.2.3 Alkaline phospatase 
Progression free survival  
Using a cutoff value of 135 U/L for alkaline phosphatase 470 patients were analysed, 
which 88 patients (18.7%) had alkaline phosphatase levels more than or equal to 135 
U/L and 382 patients (81.3%) had alkaline phosphatase levels less than 135 U/L.  
Table 13: Distribution of prognostic factor alkalin e phosphatase 
Alkaline phosphatase Number of patients 
>= 135 U/L 88 18.7% 
< 135 U/L 382 81.3% 
Total 470 100% 
 
54 patients (61.4%) of 88 patients with alkaline phosphatase levels more than or 
equal to 135 U/L had progression and 34 patients (38.6%) survived without 
progression. 208 patients (54.5%) of 382 patients with alkaline phosphatase levels 
less than 135 U/L had progression and 174 patients (45.5%) survived without 
progression. 
Table 14: Status of disease according to alkaline p hosphatase level 
Alkaline phosphatase Progression Stable disease P value 
>= 135 U/L 88 54 34 0.210 
100% 61.4% 38.6% 
< 135 U/L 382 208 174 
100% 54.5% 45.5% 
 
The median progression free survival (PFS) for the group of the patients with alkaline 
phosphatase levels more than or equal to 135 U/L was 27.5 months, whereas for the 
group of the patients with alkaline phosphatase levels less than 135 U/L 56.8 months. 
This shows a difference of 29.3 months. After about 10 years at the end of the time of 
analysis the group of the patients with alkaline phosphatase levels more than or 
equal to 135 U/L did not reach the 25% percentile, whereas the other group of the 
patients with alkaline phosphatase levels less than 135 U/L continuously descended 
until less than 10% percentile. 
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Alkaline phosphatase 
Figure 6: Alkaline phosphatase - Progression free su rvival in months            <135 U/L  >=135 U/L 
 
Overall survival  
474 patients were analysed, which 91 patients (19.2%) had alkaline phosphatase 
levels more than or equal to 135 U/L and 383 patients (80.8%) had alkaline 
phosphatase levels less than 135 U/L.  
Table 15: Distribution of prognostic factor alkalin e phosphatase 
Alkaline phosphatase Number of patients 
>= 135 U/L 91 19.2% 
< 135 U/L 383 80.8% 
Total 474 100% 
 
11 patients (12.1%) of 91 patients with alkaline phosphatase levels more than or 
equal to 135 U/L died and 80 patients (87.9%) survived. 40 patients (10.4%) of 383 
patients with alkaline phosphatase levels less than 135 U/L died and 343 patients 
(89.6%) survived. 
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Table 16: Survival status according to alkaline pho sphatase level 
Alkaline phosphatase Dead Alive P value 
>= 135 U/L 91 11 80 0.997 
100% 12.1% 87.9% 
< 135 U/L 383 40 343 
100% 10.4% 89.6% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. This graph below shows similar results between these two groups. No 
significant difference is demonstrated. 
Alkaline phosphatase 
Figure 7: Alkaline phosphatase - Overall survival i n months                             <135 U/L  >=135 U/L 
 
3.2.4 Serum glutamic oxaloacetic transaminase (SGOT ) 
Progression free survival  
Using a cutoff value of 33 U/L for female and 40 U/L for male for SGOT 434 patients 
were analysed, which 11 patients (2.6%) had SGOT levels more than or equal to 33 
U/L for female and 40 U/L for male and 423 patients (97.4%) had SGOT levels less 
than 33 U/L for female and 40 U/L for male.  
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Table 17: Distribution of prognostic factor SGOT 
SGOT Number of patients 
>= 33 U/L for female 
and >=40 U/L for male 
11 2.6% 
< 33 U/L for female and 
< 40 for male 
423 97.4% 
Total 434 100% 
 
6 patients (54.5%) of 11 patients with SGOT levels more than or equal to 33 U/L for 
female and 40 U/L for male had progression and 5 patients (45.5%) survived without 
progression. 238 patients (56.3%) of 423 patients with SGOT levels less than 33 U/L 
for female and 40 U/L for male had progression and 185 patients (43.7%) survived 
without progression. 
Table 18: Status of disease according to SGOT level  
SGOT Progression Stable disease P value 
>= 33 U/L for female 
and >=40 U/L for male 
11 6 5 0.952 
100% 54.5% 45.5% 
< 33 U/L for female 
and < 40 for male 
423 238 185 
100% 56.3% 43.7% 
 
The median progression free survival (PFS) for the group of the patients with SGOT 
levels more than or equal to 33 U/L for female and 40 U/L for male was 63.3 months, 
whereas for the group of the patients with SGOT levels less than 33 U/L for female 
and 40 U/L for male 45.7 months. This shows a difference of 17.6 months.  
3.Results                                                                                                                                   33 
SGOT 
Figure 8: SGOT - Progression free survival in months                           Male <40 U/L / Female <33 U/L   
                   Male >=40 U/L / Female >=33 U/L 
 
Overall survival  
436 patients were analysed, which 11 patients (2.6%) had SGOT levels more than or 
equal to 33 U/L for female and 40 U/L for male and 425 patients (97.4%) had SGOT 
levels less than 33 U/L for female and 40 U/L for male. 
Table 19: Distribution of prognostic factor SGOT 
SGOT Number of patients 
>= 33 U/L for female 
and >=40 U/L for male 
11 2.6% 
< 33 U/L for female and 
< 40 for male 
425 97.4% 
Total 436 100% 
 
All of 11 patients with SGOT levels more than or equal to 33 U/L for female and 40 
U/L for male survived. And 39 patients (9.2%) of 425 patients with SGOT levels less 
than 33 U/L for female and 40 U/L for male died and 386 patients (90.8%) survived. 
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Table 20: Survival status according to SGOT level 
SGOT Dead Alive P value 
>= 33 U/L for female 
and >=40 U/L for male 
11 0 11 0.377 
100% 0% 100% 
< 33 U/L for female 
and < 40 for male 
425 39 386 
100% 9.2% 90.8% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with SGOT levels less than 33 
U/L for female and 40 U/L for male was 121.7 months. This does not show significant 
difference (P value 0.377). 
SGOT 
Figure 9: SGOT - Overall survival in months                                           Male <40 U/L / Female <33 U/L   
                   Male >=40 U/L / Female >=33 U/L  
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3.2.5 Serum glutamate pyruvate transaminase (SGPT) 
Progression free survival  
Using a cutoff value of 35 U/L for female and 45 U/L for male for SGPT 463 patients 
were analysed, which 17 patients (3.7%) had SGPT levels more than or equal to 35 
U/L for female and 45 U/L for male and 446 patients (96.3%) had SGPT levels less 
than 35 U/L for female and 45 U/L for male.  
Table 21: Distribution of prognostic factor SGPT 
SGPT Number of patients 
>= 35 U/L for female 
and >=45 U/L for male 
17 3.7% 
< 35 U/L for female and 
< 45 for male 
446 96.3% 
Total 463 100% 
 
12 patients (70.6%) of 17 patients with SGPT levels more than or equal to 35 U/L for 
female and 45 U/L for male had progression and 5 patients (29.4%) survived without 
progression. 250 patients (56.1%) of 446 patients with SGOT levels less than 35 U/L 
for female and 45 U/L for male had progression and 196 patients (43.9%) survived 
without progression.  
Table 22: Status of disease according to SGPT level  
SGPT Progression Stable disease P value 
>= 35 U/L for female 
and >=45 U/L for male 
17 12 5 0.456 
100% 70.6% 29.4% 
< 35 U/L for female 
and < 45 for male 
423 250 196 
100% 56.1% 43.9% 
 
The median progression free survival (PFS) for the group of the patients with SGPT 
levels more than or equal to 35 U/L for female and 45 U/L for male was 44.1 months, 
whereas for the group of the patients with SGOT levels less than 35 U/L for female 
and 45 U/L for male 43.2 months. This shows a difference of only 0.9 months. But if 
we compare the 25% percentile progression free survival between these two groups, 
it shows a significant difference of 44.2 months (63.3 months for the group of the 
patients with SGPT levels more than or equal to 35 U/L for female and 45 U/L for 
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male and 107.5 months for the group of the patients with SGPT levels less than 35 
U/L for female and 45 U/L for male).        
SGPT 
Figure 10: SGPT - Progression free survival in months                          Male <45 U/L / Female <35 U/L   
                   Male >=45 U/L / Female >=35 U/L 
 
Overall survival  
466 patients were analysed, which 17 patients (3.6%) had SGPT levels more than or 
equal to 35 U/L for female and 45 U/L for male and  449 patients (96.4%) had SGPT 
levels less than 35 U/L for female and 45 U/L for male. 
Table 23: Distribution of prognostic factor SGPT 
SGPT Number of patients 
>= 35 U/L for female 
and >=45 U/L for male 
17 3.6% 
< 35 U/L for female and 
< 45 for male 
449 96.4% 
Total 466 100% 
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All of 17 patients with SGPT levels more than or equal to 35 U/L for female and 45 
U/L for male survived. And 43 patients (9.2%) of 449 patients with SGPT levels less 
than 35 U/L for female and 45 U/L for male died and 406 patients (90.8%) survived. 
Table 24: Survival status according to SGPT level 
SGPT Dead Alive P value 
>= 35 U/L for female 
and >=45 U/L for male 
17 0 17 0.218 
100% 0% 100% 
< 35 U/L for female 
and < 45 for male 
449 43 406 
100% 9.2% 90.8% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with SGPT levels less than 35 
U/L for female and 45 U/L for male was 121.7 months. This does not show significant 
difference (P value 0.218). 
SGPT 
Figure 11: SGPT – Overall survival in months                              Male <45 U/L / Female <35 U/L   
                   Male >=45 U/L / Female >=35 U/L 
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3.2.6 Gamma glutamyl transpeptidase (Gamma-GT)  
Progression free survival  
Using a cutoff value of 35 U/L for female and 55 U/L for male for Gamma-GT 461 
patients were analysed, which 43 patients (9.3%) had Gamma-GT levels more than 
or equal to 35 U/L for female and 55 U/L for male and 418 patients (90.7%) had 
Gamma-GT levels less than 35 U/L for female and 55 U/L for male.  
Table 25: Distribution of prognostic factor Gamma-G T 
Gamma-GT Number of patients 
>= 35 U/L for female and >=55 
U/L for male 
43 9.3% 
< 35 U/L for female and < 55 for 
male 
418 90.7% 
Total 461 100% 
 
24 patients (55.8%) of 43 patients with Gamma-GT levels more than or equal to 35 
U/L for female and 55 U/L for male had progression and 19 patients (44.2%) survived 
without progression. 236 patients (56.5%) of 418 patients with Gamma-GT levels 
less than 35 U/L for female and 55 U/L for male had progression and 182 patients 
(43.5%) survived without progression. 
Table 26: Status of disease according to Gamma-GT l evel 
Gamma-GT Progression Stable desease P value 
>= 35 U/L for female 
and >=55 U/L for male 
43 24 19 0.897 
100% 55.8% 44.2% 
< 35 U/L for female 
and < 55 for male 
418 236 182 
100% 56.5% 43.5% 
 
The median progression free survival (PFS) for the group of the patients with 
Gamma-GT levels more than or equal to 35 U/L for female and 55 U/L for male was 
31.8 months, whereas for the group of the patients with Gamma-GT levels less than 
35 U/L for female and 55 U/L for male 52.5 months. This shows a difference of 20.7 
months.  
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Gamma-GT 
Figure 12: Gamma-GT - Progression free survival in m onths                   Male <55 U/L / Female <35 U/L   
                   Male >=55 U/L / Female >=35 U/L 
 
Overall survival  
466 patients were analysed, which 42 patients (9%) had Gamma-GT levels more 
than or equal to 35 U/L for female and 55 U/L for male and  424 patients (91%) had 
Gamma-GT levels less than 35 U/L for female and 55 U/L for male. 
Table 27: Distribution of prognostic factor Gamma-G T 
Gamma-GT Number of patients 
>= 35 U/L for female and >=55 
U/L for male 
42 9% 
< 35 U/L for female and < 55 for 
male 
424 91% 
Total 466 100% 
 
4 patients (9.5%) of 42 patients with Gamma-GT levels more than or equal to 35 U/L 
for female and 55 U/L for male died and 38 patients (90.5%) survived. 43 patients 
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(10.1%) of 424 patients with Gamma-GT levels less than 35 U/L for female and 55 
U/L for male died and 381 patients (89.9%) survived. 
Table 28: Survival status according to Gamma-GT lev el 
Gamma-GT Dead Alive P value 
>= 35 U/L for female 
and >=55 U/L for male 
42 4 38 0.809 
100% 9.5% 90.5% 
< 35 U/L for female 
and < 55 for male 
424 43 381 
100% 10.1% 89.9% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with Gamma-GT levels less 
than 35 U/L for female and 55 U/L for male was 121.7 months. This does not show 
significant difference (P value 0.809). 
Gamma-GT 
Figure 13: Gamma-GT - Overall survival in months                                   Male <55 U/L / Female <35 U/L   
                   Male >=55 U/L / Female >=35 U/L 
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3.2.7 Cholinesterase (CHE) 
Progression free survival     
Using a cutoff value of 5 kU/L for cholinesterase 200 patients were analysed, which 
152 patients (76%) had CHE levels more than or equal to 5 kU/L and 48 patients 
(24%) had CHE levels less than 5 kU/L.  
Table 29: Distribution of prognostic factor CHE 
CHE Number of patients 
>= 5 kU/L 152 76% 
< 5 kU/L 48 24% 
Total 200 100% 
 
85 patients (55.9%) of 152 patients with CHE levels more than or equal to 5 kU/L had 
progression and 67 patients (44.1%) survived without progression. 29 patients 
(60.4%) of 48 patients with CHE levels less than 5 kU/L had progression and 19 
patients (39.6%) survived without progression. 
Table 30: Status of disease according to CHE level 
CHE Progression Stable disease P value 
>= 5 kU/L 152 85 67 0.383 
100% 55.9% 44.1% 
< 5 kU/L 48 29 19 
100% 60.4% 39.6% 
 
The median progression free survival (PFS) for the group of the patients with CHE 
levels more than or equal to 5 kU/L was 56.6 months, whereas for the group of 
patients with CHE levels less than 5 kU/L 26.9 months. This shows a difference of 
29.7 months.  
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CHE 
Figure 14: CHE - Progression free survival in months                                            <5 kU/L   >=5 kU/L 
 
Overall survival  
202 patients were analysed, 152 patients (75.2%) had CHE levels more than or 
equal to 5 kU/L and 50 patients (24.8%) had CHE levels less than 5 kU/L.  
Table 31: Distribution of prognostic factor CHE 
CHE Number of patients 
>= 5 kU/L 152 75.2% 
< 5 kU/L 50 24.8% 
Total 202 100% 
 
11 patients (7.2%) of 152 patients with CHE levels more than or equal to 5 kU/L died 
and 141 patients (92.8%) survived. 6 patients (12%) of 50 patients with CHE levels 
less than 5 kU/L died and 44 patients (88%) survived. 
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Table 32: Survival status according to CHE level 
CHE Dead Alive P value 
>= 5 kU/L 152 11 141 0.226 
100% 7.2% 92.8% 
< 5 kU/L 50 6 44 
100% 12% 88% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. No significant difference has been seen. 
CHE 
Figure 15: CHE - Overall survival in months                                                            <5 kU/L   >=5 kU/L 
 
3.2.8 Lactate dehydrogenase (LDH) 
Progression free survival  
Using a cutoff value of 250 U/L for LDH 566 patients were analysed, which 66 
patients (11.7%) had LDH levels more than or equal to 250 U/L and 500 patients 
(88.3%) had LDH levels less than 250 U/L.  
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Table 33: Distribution of prognostic factor LDH 
LDH Number of patients 
>= 250 U/L 66 11.7% 
< 250 U/L 500 88.3% 
Total 566 100% 
 
49 patients (74.2%) of 66 patients with LDH levels more than or equal to 250 U/L 
showed progression and 17 patients (25.8%) survived without progression. 268 
patients (53.6%) of 500 patients with LDH levels less than 250 U/L had progression 
and 232 patients (46.4%) survived without progression. 
Table 34: Status of disease according to LDH level 
LDH Progression Stable disease P value 
>= 250 U/L 66 49 17 <0.001 
100% 74.2% 25.8% 
< 250 U/L 500 268 232 
100% 53.6% 46.4% 
 
The median progression free survival (PFS) for the group of the patients with LDH 
levels more than or equal to 250 U/L was 18.1 months, whereas for the group of the 
patients with LDH levels less than 250 U/L 60.6 months. This shows a significant 
difference of 42.5 months (p value < 0.001).  
3.Results                                                                                                                                   45 
LDH 
Figure 16: LDH - Progression free survival in months                                             <5 kU/L   >=5 kU/L 
 
Overall survival  
570 patients were analysed, which 66 patients (11.6%) had LDH levels more than or 
equal to 250 U/L and 504 patients (88.4%) had LDH levels less than 250 U/L.  
Table 35: Distribution of prognostic factor LDH 
LDH Number of patients 
>= 250 U/L 66 11.6% 
< 250 U/L 504 88.4% 
Total 570 100% 
 
10 patients (15.2%) of 66 patients with LDH levels more than or equal to 250 U/L 
died and 56 patients (84.8%) survived. 48 patients (9.5%) of 504 patients with LDH 
levels less than 250 U/L died and 456 patients (90.5%) survived. 
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Table 36: LDH - Overall survival in months 
LDH Dead Alive P value 
>= 250U/L 66 10 56 0.355 
100% 15.2% 84.8% 
< 250 U/L 504 48 456 
100% 9.5% 90.5% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. No significant difference has been seen. 
LDH 
Figure 17: LDH - Overall survival in months                                                            <5 kU/L   >=5 kU/L 
 
3.2.9 Blood urea nitrogen (BUN) 
Progression free survival  
Using a cutoff value of 50 mg/dL for BUN 303 patients were analysed, which 19 
patients (6.3%) had BUN levels more than 50 mg/dL and 284 patients (93.7%) had 
BUN levels less than or equal to 50 mg/dL.  
 
3.Results                                                                                                                                   47 
Table 37: Distribution of prognostic factor BUN 
BUN Number of patients 
> 50 mg/dL 19 6.3% 
<= 50 mg/dL 284 93.7% 
Total 303 100% 
 
15 patients (78.9%) of 19 patients with BUN levels more than 50 mg/dL had 
progression and 4 patients (21.1%) survived without progression. 152 patients 
(53.5%) of 284 patients with BUN levels less than or equal to 50 mg/dL had 
progression and 132 patients (46.5%) survived without progression. 
Table 38: Status of disease according to BUN level 
BUN Progression Stable disease P value 
> 50 mg/dL 19 15 4 0.032 
100% 78.9% 21.1% 
<= 50 mg/dL 284 152 132 
100% 53.5% 46.5% 
 
The median progression free survival (PFS) for the group of the patients with BUN 
levels more than 50 mg/dL was 18.7 months, whereas for the group of the patients 
with BUN levels less than or equal to 50 mg/dL 52.5 months. This shows a significant 
difference of 33.8 months (p value 0.032).  
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BUN 
Figure 18: BUN - Progression free survival in months                                  <=50 mg/dL   >50 mg/dL 
 
Overall survival  
307 patients were analysed, which 19 patients (11.6%) had BUN levels more than 50 
mg/dL and 288 patients (88.4%) had BUN levels less than or equal to 50 mg/dL.  
Table 39: Distribution of prognostic factor BUN 
BUN Number of patients 
> 50 mg/dL 19 6.2% 
<= 50 mg/dL 288 93.8% 
Total 307 100% 
 
4 patients (21.1%) of 19 patients with BUN levels more than 50 mg/dL died and 15 
patients (78.9%) survived. 21 patients (7.3%) of 288 patients with BUN levels less 
than or equal to 50 mg/dL died and 267 patients (92.7%) survived. 
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Table 40: Survival status according to BUN level 
BUN Dead Alive P value 
> 50 mg/dL 19 4 15 0.046 
100% 21.1% 78.9% 
<= 50 mg/dL 288 21 267 
100% 7.3% 92.7% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with BUN levels more than 50 
mg/dL was 65.6 months and the group of the patients with BUN levels less than or 
equal to 50 mg/dL was not reached. This shows a significant difference (P value 
0.046). 
BUN 
Figure 19: BUN - Overall survival in months                                                  <=50 mg/dL   >50 mg/dL 
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3.2.10 Uric acid 
Progression free survival  
Using a cutoff value of 5.7 mg/dL for female and 7 mg/dL for male for uric acid 440 
patients were analysed, which 89 patients (20.2%) had uric acid levels more than or 
equal to 5.7 mg/dL for female and 7 mg/dL for male and 351 patients (79.8%) had 
uric acid levels less than 5.7 mg/dL for female and 7 mg/dL for male.  
Table 41: Distribution of prognostic factor uric ac id 
Uric acid Number of patients 
>= 5.7 mg/dL for female and >=7 
mg/dL for male 
89 20.2% 
< 5.7 mg/dL for female and < 7 
mg/dL for male 
351 79.8% 
Total 440 100% 
 
57 patients (64.0%) of 89 patients with uric acid levels more than or equal to 5.7 
mg/dL for female and 7 mg/dL for male had progression and 32 patients (36.0%) 
survived without progression. 189 patients (53.8%) of 351 patients with uric acid 
levels less than 5.7 mg/dL for female and 7 mg/dL for male had progression and 162 
patients (46.2%) survived without progression. 
Table 42: Status of disease according to uric acid level 
Uric acid Progression Stable disease P value 
>= 5.7 mg/dL for 
female and >=7 mg/dL 
for male 
89 57 32 0.205 
100% 64.0% 36.0% 
< 5.7 mg/dL for female 
and < 7 mg/dL for 
male 
351 189 162 
100% 53.8% 46.2% 
 
The median progression free survival (PFS) for the group of the patients with uric 
acid levels more than or equal to 5.7 mg/dL for female and 7 mg/dL for male was  
35.5 months, whereas for the group of the patients with uric acid levels less than 5.7 
mg/dL for female and 7 mg/dL for male 56.6 months. This shows a difference of 21.1 
months.  
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Uric acid 
Figure 20: Uric acid - Progression free survival in months           Male <7.0 mg/dL / Female <5.7 mg/dL   
                   Male >=7.0 mg/dL / Female >=5.7 mg/dL 
 
Overall survival  
443 patients were analysed, which 88 patients (19.9%) had uric acid levels more 
than or equal to 5.7 mg/dL for female and 7 mg/dL for male and 355 patients (80.1%) 
had uric acid levels less than 5.7 mg/dL for female and 7 mg/dL for male. 
Table 43: Distribution of prognostic factor uric ac id 
Uric acid Number of patients 
>= 5.7 mg/dL for female and >=7 
mg/dL for male 
88 19.9% 
< 5.7 mg/dL for female and < 7 
mg/dL for male 
355 80.1% 
Total 443 100% 
 
11 patients (12.5%) of 88 patients with uric acid levels more than or equal to 5.7 
mg/dL for female and 7 mg/dL for male died and 77 patients (87.5%) survived. 32 
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patients (9.0%) of 355 patients with uric acid levels less than 5.7 mg/dL for female 
and 7 mg/dL for male died and 323 patients (91.0%) survived. 
Table 44: Survival status according to uric acid le vel 
Uric acid Dead Alive P value 
>= 5.7 mg/dL for 
female and >=7 mg/dL 
for male 
88 11 77 0.428 
100% 12.5% 87.5% 
< 5.7 mg/dL for female 
and < 7 mg/dL for 
male 
355 32 323 
100% 9.0% 91.0% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with uric acid levels less than 
5.7 mg/dL for female and 7 mg/dL for male was 121.7 months. This does not show 
significant difference (P value 0.428). 
Uric acid 
Figure 21: Uric acid - Overall survival in months                          Male <7.0 mg/dL / Female <5.7 mg/dL   
                   Male >=7.0 mg/dL / Female >=5.7 mg/dL  
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3.2.11 Serum Creatinine 
Progression free survival  
Using a cutoff value of 1.0 mg/dL for female and 1.2 mg/dL for male for creatinine 
508 patients were analysed, which 100 patients (19.7%) had creatinine levels more 
than or equal to 1.0 mg/dL for female and 1.2 mg/dL for male and 408 patients 
(80.3%) had creatinine levels less than 1.0 mg/dL for female and 1.2 mg/dL for male.  
Table 45: Distribution of prognostic factor creatin ine 
Creatinine Number of patients 
>= 1.0 mg/dL for female 
and >=1.2 mg/dL for male 
100 19.7% 
< 1.0 mg/dL for female and < 1.2 
mg/dL for male 
408 80.3% 
Total 508 100% 
 
72 patients (72.0%) of 100 patients with creatinine levels more than or equal to 1.0 
mg/dL for female and 1.2 mg/dL for male had progression and 28 patients (28.0%) 
survived without progression. 220 patients (53.9%) of 408 patients with creatinine 
levels less than 1.0 mg/dL for female and 1.2 mg/dL for male had progression and 
188 patients (46.1%) survived without progression. 
Table 46: Status of disease according to creatinine  level 
Creatinine Progression Stable disease P value 
>= 1.0 mg/dL for 
female and >=1.2 
mg/dL for male 
100 72 28 < 0.01  
100% 72.0% 28.0% 
< 1.0 mg/dL for female 
and < 1.2 mg/dL for 
male 
408 220 188 
100% 53.9% 46.1% 
 
The median progression free survival (PFS) for the group of the patients with 
creatinine levels more than or equal to 1.0 mg/dL for female and 1.2 mg/dL for male 
was  25.1 months, whereas for the group of the patients with creatinine levels less 
than 1.0 mg/dL for female and 1.2 mg/dL for male 59.4 months. This shows a 
significant difference of 34.3 months.  
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Creatinine 
Figure 22: Creatinine - Progression free survival in  months       Male <1.2 mg/dL / Female <1.0 mg/dL   
                   Male >=1.2 mg/dL / Female >=1.0 mg/dL 
 
Overall survival  
511 patients were analysed, which 100 patients (19.6%) had creatinine levels more 
than or equal to 1.0 mg/dL for female and 1.2 mg/dL for male and 411 patients 
(80.4%) had creatinine levels less than 1.0 mg/dL for female and 1.2 mg/dL for male. 
Table 47: Distribution of prognostic factor creatin ine 
Creatinine Number of patients 
>= 1.0 mg/dL for female 
and >=1.2 mg/dL for male 
100 19.6% 
< 1.0 mg/dL for female and < 1.2 
mg/dL for male 
411 80.4% 
Total 511 100% 
 
20 patients (20.0%) of 100 patients with creatinine levels more than or equal to 1.0 
mg/dL for female and 1.2 mg/dL for male died and 80 patients (80.0%) survived. 33 
3.Results                                                                                                                                   55 
patients (8.0%) of 411 patients with creatinine levels less than 1.0 mg/dL for female 
and 1.2 mg/dL for male died and 378 patients (92.0%) survived. 
Table 48: Survival status according to creatinine l evel 
Creatinine Dead Alive P value 
>= 1.0 mg/dL for 
female and >=1.2 
mg/dL for male 
100 20 80 < 0.01 
100% 20.0% 80.0% 
< 1.0 mg/dL for female 
and < 1.2 mg/dL for 
male 
411 33 378 
100% 8.0% 92.0% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with creatinine levels less 
than 1.0 mg/dL for female and 1.2 mg/dL for male was 121.7 months and the group 
of the patients with creatinine levels more than or equal to 1.0 mg/dL for female and 
1.2 mg/dL for male was 80.8 months. This shows a significant difference of 40.9 
months (P value < 0.01). 
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Creatinine 
Figure 23: Creatinine - Overall survival in months                       Male <1.2 mg/dL / Female <1.0 mg/dL   
                   Male >=1.2 mg/dL / Female >=1.0 mg/dL 
 
3.2.12 Total bilirubin 
Progression free survival  
Using a cutoff value of 1 mg/dL for total bilirubin 434 patients were analysed, which 
37 patients (8.5%) had total bilirubin levels more than 1 mg/dL and 397 patients 
(91.5%) had total bilirubin levels less than or equal to 1 mg/dL.  
Table 49: Distribution of prognostic factor total b ilirubin 
Total bilirubin Number of patients 
> 1 mg/dL 37 8.5% 
<= 1 mg/dL 397 91.5% 
Total 434 100% 
 
23 patients (62.2%) of 37 patients with total bilirubin levels more than 1 mg/dL had 
progression and 14 patients (37.8%) survived without progression. 226 patients 
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(56.9%) of 397 patients with total bilirubin levels less than or equal to 1 mg/dL had 
progression and 171 patients (43.1%) survived without progression.  
Table 50: Status of disease according to total bili rubin level 
Total bilirubin Progression Stable disease P value 
> 1 mg/dL 37 23 14 0.262 
100% 62.2% 37.8% 
<= 1 mg/dL 397 226 171 
100% 56.9% 43.1% 
 
The median progression free survival (PFS) for the group of the patients with total 
bilirubin levels more than 1 mg/dL was 36.7 months, whereas for the group of the 
patients with total bilirubin levels less than or equal to 1 mg/dL 41.8 months. This 
does not show a significant difference (only 5.1 months, p value 0.262).  
Total bilirubin 
Figure 24: Total bilirubin - Progression free surviv al in months                     <=1 mg/dL   >1 mg/dL 
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Overall survival  
436 patients were analysed, which 37 patients (8.4%) had total bilirubin levels more 
than 1 mg/dL and 399 patients (91.6%) had total bilirubin levels less than or equal to 
1 mg/dL.  
Table 51: Distribution of prognostic factor total b ilirubin 
Total bilirubin Number of patients 
> 1 mg/dL 37 8.4% 
<=1 mg/dL 399 91.6% 
Total 436 100% 
 
5 patients (13.5%) of 37 patients with total bilirubin levels more than 1 mg/dL died 
and 32 patients (86.5%) survived. 35 patients (8.8%) of 399 patients with total 
bilirubin levels less than or equal to 1 mg/dL died and 364 patients (91.2%) survived. 
Table 52: Survival status according to total biliru bin level 
Total bilirubin Dead Alive P value 
> 1 mg/dL 37 5 32 0.255 
100% 13.5% 86.5% 
<= 1 mg/dL 399 35 364 
100% 8.8% 91.2% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with total bilirubin levels less 
than or equal to 1 mg/dL was 121.7 months and the group of the patients with total 
bilirubin levels more than 1 mg/dL was 80.8 moths. This shows a difference of 40.9 
months. 
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Total bilirubin 
Figure 25: Total bilirubin - Overall survival in mo nths                                      <=1 mg/dL   >1 mg/dL 
 
3.2.13 Hepatomegaly 
Progression free survival  
524 patients were analysed, which 20 patients (3.8%) had palpable hepatomegaly 
and  504 patients (96.2%) did not have palpable hepatomegaly.  
Table 53: Distribution of prognostic factor hepatom egaly 
Hepatomegaly Number of patients 
Palpable 20 3.8% 
Not palpable 504 96.2% 
Total 524 100% 
 
14 patients (70.0%) of 20 patients with palpable hepatomegaly had progression and 
6 patients (30.0%) survived without progression. 282 patients (56.0%) of 504 patients 
without palpable hepatomegaly had progression and 222 patients (44.0%) survived 
without progression.  
3.Results                                                                                                                                   60 
Table 54: Status of disease according to presence o f palpable hepatomegaly 
Hepatomegaly Progression Stable disease P value 
Palpable 20 14 6 0.220 
100% 70.0% 30.0% 
Not palpable 504 282 222 
100% 56.0% 44.0% 
 
The median progression free survival (PFS) for the group of the patients with 
palpable hepatomegaly was 23.9 months, whereas for the group of the patients 
without palpable hepatomegaly 51.8 months. This shows a difference of 27.9 months 
(p value 0.220).  
Hepatomegaly 
Figure 26: Hepatomegaly - Progression free survival  in months                  Palpable   Not palpable 
 
Overall survival  
526 patients were analysed, which 19 patients (3.6%) had palpable hepatomegaly 
and 507 patients (96.4%) did not have palpable hepatomegaly.  
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Table 55: Distribution of palpable Hepatomegaly 
Hepatomegaly Number of patients 
Palpable 19 3.6% 
Not palpable 507 96.4% 
Total 526 100% 
 
1 patient (5.3%) of 19 patients with palpable hepatomegaly died and 18 patients 
(94.7%) survived. 51 patients (10.1%) of 507 patients without palpable hepatomegaly 
died and 456 patients (89.9%) survived. 
Table 56: Survival status according to presence of palpable hepatomegaly 
Hepatomegaly  Dead Alive P value 
Palpable  19 1 18 0.618 
100% 5.3% 94.7% 
Not palpable 507 51 456 
100% 10.1% 89.9% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients without palpable 
hepatomegaly was 121.7 months and the group of the patients with palpable 
hepatomegaly was not reached. This does not show significant difference (P value 
0.618). 
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Hepatomegaly 
Figure 27: Hepatomegaly - Overall survival in month s                                   Palpable   Not palpable 
 
3.2.14 Splenomegaly 
Progression free survival  
528 patients were analysed, which 27 patients (5.1%) had palpable splenomegaly 
and  501 patients (94.9%) did not have palpable splenomegaly.  
Table 57: Distribution of prognostic factor palpabl e splenomegaly 
Splenomegaly Number of patients 
Palpable 27 5.1% 
Not palpable 501 94.9% 
Total 528 100% 
 
21 patients (78.8%) of 27 patients with palpable splenomegaly had progression and 6 
patients (22.2%) survived without progression. 278 patients (55.5%) of 501 patients 
without palpable splenomegaly had progression and 223 patients (44.5%) survived 
without progression. 
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Table 58: Status of disease according to presence o f palpable splenomegaly 
Splenomegaly Progression Stable disease P value 
Palpable 27 21 6 < 0.01 
100% 78.8% 22.2% 
Not palpable 501 278 223 
100% 55.5% 44.5% 
 
The median progression free survival (PFS) for the group of the patients with 
palpable splenomegaly was 20.0 months, whereas for the group of the patients 
without palpable splenomegaly 52.1 months. This shows a significant difference of 
32.1 months (p value < 0.01).  
Splenomegaly 
Figure 28: Splenomegaly - Progression free survival i n months                  Palpable   Not palpable 
 
Overall survival  
530 patients were analysed, which 28 patients (5.3%) had palpable splenomegaly 
and 502 patients (94.7%) did not have palpable hepatomegaly.  
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Table 59: Distribution of prognostic factor palpabl e splenomegaly 
Splenomegaly Number of patients 
Palpable 28 5.3% 
Not palpable 502 94.7% 
Total 530 100% 
 
2 patients (7.1%) of 28 patients with palpable splenomegaly died and 26 patients 
(92.9%) survived. 52 patients (10.4%) of 502 patients without palpable splenomegaly 
died and 450 patients (89.6%) survived. 
Table 60: Survival status according to palpable spl enomegaly 
Splenomegaly  Dead Alive P value 
Palpable  28 2 26 0.594 
100% 7.1% 92.9% 
Not palpable 502 52 450 
100% 10.4% 89.6% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients without palpable 
splenomegaly was 121.7 months and the group of the patients with palpable 
splenomegaly was not reached. This does not show significant difference (P value 
0.594). 
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Splenomegaly 
Figure 29: Splenomegaly - Overall survival in months                                    Palpable   Not palpable 
 
3.2.15 Lymphadenopathy 
3.2.15.1 Cervical lymphadenopathy 
Progression free survival  
545 patients were analysed, which 91 patients (16.7%) had pathologic palpable 
cervival lymphadenopathy and  454 patients (83.3%) did not have pathologic 
palpable cervival lymphadenopathy.  
Table 61: Distribution of prognostic factor cervica l lymphadenopathy 
Pathologic cervical 
lymphadenopathy 
Number of patients 
Palpable 91 16.7% 
Not palpable 454 83.3% 
Total 545 100% 
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69 patients (75.8%) of 91 patients with pathologic palpable cervival lymphadenopathy 
had progression and 22 patients (24.2%) survived without progression. 239 patients 
(52.6%) of 454 patients without pathologic palpable cervival lymphadenopathy had 
progression and 215 patients (47.4%) survived without progression. 
Table 62: Status of disease according to presence o f cervical lymphadenopathy 
Pathologic cervical 
lymphadenopathy 
Progression Stable disease P value 
Palpable 91 69 22 < 0.01 
100% 75.8% 24.2% 
Not palpable 454 239 215 
100% 52.6% 47.4% 
 
The median progression free survival (PFS) for the group of the patients with 
pathologic palpable cervical lymphadenopathy was 19.9 months, whereas for the 
group of the patients without pathologic palpable cervical lymphadenopathy 62 
months. This shows a significant difference of 42.1 months (p value < 0.01).  
         Pathologic cervical 
                                                                                                                                                     lymp hadenopathy  
Figure 30: Cervical lymphadenopathy - Progression fr ee survival in months                    Yes  No 
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Overall survival  
549 patients were analysed, which 93 patients (12.9%) had pathologic palpable 
cervical lymphadenopathy and 456 patients (87.1%) did not have pathologic palpable 
cervical lymphadenopathy. 
Table 63: Distribution of prognostic factor cervica l lymphadenopathy 
Pathologic cervical 
lymphadenopathy 
Number of patients 
Palpable 93 16.9% 
Not palpable 456 83.1% 
Total 549 100% 
 
13 patients (14.0%) of 93 patients with pathologic palpable cervical lymphadenopathy 
did not survive and 80 patients (86.0%) survived.  44 patients (9.6%) of 456 patients 
without pathologic palpable cervical lymphadenopathy died and 412 patients (90.4%) 
survived. 
Table 64: Survival status according to cervical lym phadenopathy 
Pathologic cervical 
lymphadenopathy  
Dead Alive P value 
Palpable  93 13 80 0.339 
100% 14.0% 86.0% 
Not palpable 456 44 412 
100% 9.6% 90.4% 
 
At the end of the time of analysis none of these two groups has reached the 50% 
percentile. The 75% percentile of the group of patients with pathologic palpable 
cervical lymphadenopathy was 97.4 months and the group of the patients without 
pathologic palpable cervical lymphadenopathy was 121.7 months. This does not 
show significant difference (P value 0.339). 
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            Pathologic cervical 
                                                                                                                                                     lymp hadenopathy  
Figure 31: Cervical lymphadenopathy - Overall survi val in months                                    Yes  No 
 
3.2.15.2 Axillary lymphadenopathy 
Progression free survival  
537 patients were analysed, which 68 patients (12.7%) had pathologic palpable 
axillary lymphadenopathy and  469 patients (87.3%) did not have pathologic palpable 
axillary lymphadenopathy.  
Table 65: Distribution of prognostic factor axillar y lymphadenopathy 
Pathologic axillary 
lymphadenopathy 
Number of patients 
Palpable 68 12.7% 
Not palpable 469 87.3% 
Total 537 100% 
 
48 patients (70.6%) of 68 patients with pathologic palpable axillary lymphadenopathy 
had progression and 20 patients (29.4%) survived without progression. 254 patients 
3.Results                                                                                                                                   69 
(54.2%) of 469 patients without pathologic palpable axillary lymphadenopathy had 
progression and 215 patients (45.8%) survived without progression. 
Table 66: Status of disease according to presence o f axillary lymphadenopathy 
Pathologic axillary 
lymphadenopathy 
Progression Stable disease P value 
Palpable 68 48 20 < 0.01 
100% 70.6% 29.4% 
Not palpable 469 254 215 
100% 54.2% 45.8% 
 
The median progression free survival (PFS) for the group of the patients with 
pathologic palpable axillary lymphadenopathy was 21.4 months, whereas for the 
group of the patients without pathologic palpable axillary lymphadenopathy 59.4 
months. This shows a significant difference of 38 months (p value < 0.01).  
            Pathologic axillary 
                                                                                                                                                     lymp hadenopathy  
Figure 32: Axillary lymphadenopathy - Progression fr ee survival in months                     Yes  No 
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Overall survival  
541 patients were analysed, which 70 patients (12.9%) had pathologic palpable 
axillary lymphadenopathy and 471 patients (87.1%) did not have pathologic palpable 
axillary lymphadenopathy. 
Table 67: Distribution of prognostic factor axillar y lymphadenopathy 
Pathologic axillary 
lymphadenopathy 
Number of patients 
Palpable 70 12.9% 
Not palpable 471 87.1% 
Total 541 100% 
 
10 patients (14.3%) of 70 patients with pathologic palpable axillary lymphadenopathy 
did not survive and 60 patients (85.7%) survived. 46 patients (9.8%) of 471 patients 
without pathologic palpable axillary lymphadenopathy died and 425 patients (90.2%) 
survived. 
Table 68: Survival status according to presence of axillary lymphadenopathy 
Pathologic axillary 
lymphadenopathy  
Dead Alive P value 
Palpable  70 10 60 0.094 
100% 14.3% 85.7% 
Not palpable 471 46 425 
100% 9.8% 90.2% 
 
The median overall survival (OS) for the group of the patients with pathologic 
palpable axillary lymphadenopathy was 97.4 months, whereas the group of the 
patients without pathologic palpable axillary lymphadenopathy did not reach the 
median.  
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         Pathologic axillary 
                                                                                                                                                     lymp hadenopathy  
Figure 33: Axillary lymphadenopathy - Overall survi val in months                                     Yes  No 
 
3.2.15.3 Inguinal lymphadenopathy 
Progression free survival  
515 patients were analysed, which 29 patients (12.7%) had pathologic palpable 
inguinal lymphadenopathy and 486 patients (87.3%) did not have pathologic palpable 
inguinal lymphadenopathy.  
Table 69: Distribution of prognostic factor inguina l lymphadenopathy 
Pathologic inguinal 
lymphadenopathy 
Number of patients 
Palpable 29 5.6% 
Not palpable 486 94.4% 
Total 515 100% 
 
18 patients (62.1%) of 29 patients with pathologic palpable inguinal 
lymphadenopathy had progression and 11 patients (37.9%) survived without 
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progression. 279 patients (57.4%) of 486 patients without pathologic palpable 
inguinal lymphadenopathy had progression and 207 patients (42.6%) survived 
without progression. 
Table 70: Status of disease according to inguinal l ymphadenopathy 
Pathologic inguinal 
lymphadenopathy 
Progression Stable disease P value 
Palpable 29 18 11 0.242 
100% 62.1% 37.9% 
Not palpable 486 279 207 
100% 57.4% 42.6% 
 
The median progression free survival (PFS) for the group of the patients with 
pathologic palpable inguinal lymphadenopathy was 25.3 months, whereas for the 
group of the patients without pahtologic palpable inguinal lymphadenopathy 45.7 
months. This shows a difference of 20.4 months.  
            Pathologic inguinal 
                                                                                                                                                     lymp hadenopathy  
Figure 34: Inguinal lymphadenopathy - Progression fr ee survival in months                    Yes  No 
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Overall survival  
517 patients were analysed, which 30 patients (5.8%) had pathologic palpable 
inguinal lymphadenopathy and 487 patients (94.2%) did not have pathologic palpable 
inguinal lymphadenopathy. 
Table 71: Distribution of prognostic factor inguina l lymphadenopathy 
Pathologic inguinal 
lymphadenopathy 
Number of patients 
Palpable 30 5.8% 
Not palpable 487 94.2% 
Total 517 100% 
 
4 patients (13.3%) of 30 patients with pathologic palpable inguinal lymphadenopathy 
did not survive and 26 patients (86.7%) survived. 50 patients (10.3%) of 487 patients 
without pathologic palpable inguinal lymphadenopathy died and 437 patients (89.7%) 
survived. 
Table 72: Survival status according to inguinal lym phadenopathy 
Pathologic inguinal 
lymphadenopathy  
Dead Alive P value 
Palpable  30 4 26 0.450 
100% 13.3% 86.7% 
Not palpable 487 50 437 
100% 10.3% 89.7% 
 
The median overall survival (OS) for the group of the patients with pathologic 
palpable inguinal lymphadenopathy was 97.4 months, whereas the group of the 
patients without pathologic palpable axillary lymphadenopathy did not reach the 
median.  
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            Pathologic inguinal 
                                                                                                                                                     lymp hadenopathy  
Figure 35: Inguinal lymphadenopathy - Overall survi val in months                                     Yes  No 
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4 Discussion 
4.1 B symptoms 
B symptoms refer to systemic symptoms of fever (> 38°C), night sweats, and weight 
loss which can be associated with inflammatory disease and also malignant 
transformation (mainly both Hodgkin’s lymphoma and non-Hodgkin’s lymphoma).  
The most common types of leukaemia are chronic myelogenous leukemia (CML) and 
chronic lymphocytic leukemia (CLL), and all forms have an insidious onset and vague, 
non-specific presenting symptoms, eg, fatigue, malaise, night sweats, weight loss 
(Hurd et al 1983). 
Hallek et al 1996 found, that B symptoms did not predict progression free survival for 
CLL patients. A similar study of Günther et al 2008 also represented, that B 
symptoms was not significant in terms of progression free survival.  On the other 
hand French Cooperative Group et al 1990 showed, that CLL patients in Binet stage 
A with B symptoms had a significant higher progression rate in comparison with the 
patients without B symptoms.  
It is not proven in this study, that there was a correlation between B symptoms and 
progression of the disease. There was even barely difference of the progression free 
survival for patients with and without B symptoms. B symptoms did not predict 
progression free survival for CLL patients in Binet stage A.  
According to Lee et al 1987 after analysing 325 untreated CLL patient part of B 
symptoms namely weight loss was associated with significant shorter survival (p 
value <0.001). Unlike that there was no significant difference concerning overall 
survival for patients with and without B symptoms in this study. This could be 
because of the possibility that the patients of Lee et al 1987 were in higher Binet 
stage (B or C).     
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4.2 ECOG (Eastern Cooperative Oncology Group) performance 
status 
In medicine, performance status is an attempt to quantify patients` general well-being. 
The most used systems are the Karnofsky score and the ECOG score.  
Table 73: ECOG performance status 
ECOG PERFORMANCE STATUS* 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed 
or chair 
5 Dead 
*As published in Am. J. Clin. Oncol.: Oken, M.M., C reech, R.H., Tormey, D.C., Horton, J., Davis, 
T.E., McFadden, E.T., Carbone, P.P.: Toxicity And R esponse Criteria Of The Eastern 
Cooperative Oncology Group. Am J Clin Oncol 5:649-6 55, 1982. 
 
Regarding the Karnofsky score, Hallek et al 1996 analysed, that Karnofsky index 
significantly predicted progression free survival for CLL patients (p value <0.001). 
French Cooperative Group et al 1990 affirmed that general symptoms were 
associated to disease progression of and overall survival for untreated CLL patients 
in stage Binet A. In comparison with his analysis in 1996, Hallek et al 1999 analysed 
122 untreated CLL patients in Binet stage A concerning progression free survival and 
they found out, that ECOG performance status did not show a significant relationship 
with progression free survival (p value >0.05). The difference between these two 
statements of Hallek might be probably because the analysed patients in 1996 
consisted of not only  of CLL patients in Binet stage A but also CLL patients in 
another Binet stages.  
4.Discussion                                                                                                                            77 
It also does not show a significant relationship between ECOG performance status 
and progression free survival in this study. Both groups had even similar result (p 
value 0.918). This approves the statement of Hallek et al 1999.   
The conclusion of Lee et al 1987 about significant association between ECOG 
performance status and overall survival cannot be approved in this study. Unlike 
progression free survival evaluation, we can see difference between these two 
groups in terms of overall survival, but that is unfortunately not significant (p value 
0.131).  This different result with Lee et al 1987 could be induced due to a few 
reasons. First of all, the possibility that the patients of Lee et al 1987 were in higher 
Binet stage (B or C) and second, the observation time in this study could be too short. 
It might show a clearlier difference with longer observation.          
4.3 Alkaline phosphatase 
Alkaline phosphatase (ALP: E.C.3.1.3.1) is an enzyme that catalyzes the hydrolysis 
of various monophosphate esters (Masaru et al 1999). Abnormally low ALP scores 
are preferentially seen in chronic myelogenous leukemia (CML) and paroxysmal 
nocturnal hemoglobinuria (PNH), whereas high ALP scores are frequently found in 
inflammatory leukocytosis, polycythemia vera (PV) and aplastic anemia (AA), and 
occasionally in idiopathic myelofibrosis (IMF) (Masaru et al 1999). 
In 1987 Lee et al analysed 325 previously untreated patients with chronic 
lymphocytic leukemia to identify significant prognostic factors for survival. Using 
cutoff value of 80 U/L for alkaline phosphatase a significant difference (p-value < 
0.001) of median overall survival was analysed.  All the biochemical parameters, 
except serum bilirubin levels, demonstrated a strong correlation with survival (Lee et 
al 1987). Unlike the analysis above this study with a determined cutoff value of 135 
U/L for alkaline phosphatase showed no significant difference for the median 
progression free survival (p-value 0.21) and almost no difference for the overall 
survival (p-value 0.997). Alkaline phosphatase predicted neither the progression free 
survival nor overall survival for chronic lymphocytic leukaemia patients .  
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4.4 Serum glutamic oxaloacetic transaminase (SGOT) 
Serum glutamic oxaloacetic transaminase (SGOT) also called aspartate 
transaminase (AST) is an enzyme, that facilitates the conversion of aspartate and 
alpha-ketoglutarate to oxaloacetate and glutamate, and vice-versa. SGOT is found in 
the liver, heart, skeletal muscle, kidneys, brain and red blood cells.  
Kardum et al 2008 analysed 155 patients with chronic leukemic lymphoproliferative 
diseases to identify prognostic parameters. He found a correlation between poorer 
survival and elevated SGOT level. Lee et al 1987 analysed also significantly strong 
correlation between SGOT and overall survival. In comparison with these analysis, 
this study showed no significant difference for both progression free survival (P value 
0.952) and overall survival (P value 0.377).  
4.5 Serum glutamate pyruvate transaminase (SGPT) 
Serum glutamate pyruvate transaminase (SGPT) is an enzyme that catalyzes the 
transfer from amino group from alanine to alpha-ketoglutarate. The products are 
pyruvate and glutamate. It is used for liver function test to determine liver health. 
Similar to SGOT we found also in this study no significant correlation between SGPT 
level and both progression free survival (P value 0.456) and overall survival (P value 
0.218). 
4.6 Gamma-glutamyltransferase (Gamma-GT) 
Gamma-GT is an enzyme that catalyzes the transfer of the gamma-glutamyl of 
glutathione to an acceptor that may be an amino acid, a peptide or water. Gamma-
GT is present in the cell membranes of many tissues, including the kidneys, bile duct, 
pancreas, liver, spleen, heart, brain, and seminal vesicles. A significantly higher 
expression of gamma GT was observed in CLL  and chronic myelogenous leukemia 
(CML) (Täger et al 1995). 
With P value of 0.897 for progression free survival and P value of 0.809 for overall 
survival there was no significant difference proven between CLL patients with normal 
and elevated Gamma-GT level. Gamma-GT did not predict the survival.  
 
 
 
4.Discussion                                                                                                                            79 
4.7 Cholinesterase (CHE) 
Cholineesterase is an enzyme that catalyzes the hydrolysis of neurotransmitter 
acetylcholine into choline and acetic acid. 
It is also shown in this study, that no significant difference seen between patients with 
elevated CHE level and normal CHE level for both progression free survival (P value 
0.383) and overall survival (P value 0.226).     
4.8 Lactate dehydrogenase (LDH) 
Lactate dehydrogenase (LDH) catalyses a critical step in the glycolysis pathway, the 
reversible transformation between pyruvate and lactate. LDH is a tetramer composed 
of two types of monomers, H (for "heart", also designated as "B"), and M (for 
"muscle", also designated as "A") (Nehar et al 1998). Serum LDH is a useful 
prognostic marker in hematological malignancies, including NHL and myeloma 
(Coiffier et al 1991, Dimopoulos et al 1991). Patel et al 1994 have reported that an 
increase in LDH isoenzyme 2 values was observed in 84% of patients with untreated 
leukemia.  
Using a cutoff value of 202 U/L for LDH Hallek et al 1999 analysed 122 previously 
untreated CLL patients with Binet stage A. He found, that there was a significant 
difference between patients with elevated and normal LDH level in terms of 
progression free survival. With p value <0.001 a very significant difference 
concerning progression free survival is shown in this study as well.    
Lee et al 1987 did a related study using another cutoff value for LDH and concerning 
the median overall survival he found a significant difference for the benefit of the 
patients with normal LDH level (p value < 0.001).This study showed that, the patients 
with increased LDH level had definitely shortened progression free survival in 
comparison to the patients with normal LDH level. However there was no significant 
difference between patients with increased and normal  LDH level in terms of overall 
survival (p value 0.355). The reason for the different result in comparison with this 
study could be  that in this study the median overall survival was not yet reached. 
The grafic shows after all a difference at 75% percentile between the patients with 
increased and normal  LDH level in terms of overall survival.   
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4.9 Blood urea nitrogen (BUN) 
The blood urea nitrogen is a measurement of the amount of nitrogen in the blood in 
the form of urea, and a measurement of renal function. Urea is a by- product from 
metabolism of proteins by the liver, and therefore removed from the blood by the 
kidneys. Elevated BUN level indicates a dysfunction of kidney or liver.  
Using another cutoff value of 20 mg/dL for BUN Lee et al 1987 found a significant 
difference in terms of progression free survival for the benefit of the patients with 
lower BUN level. With a ratio of 15:1 only few patients with elevated BUN value were 
analysed in this study. In terms of both progression free survival and overall survival 
we can see significant difference for the benefit of the patients with BUN value less 
than or equal 50 mg/dL. 
4.10  Uric acid 
Uric acid is produced by xanthin oxidase from xanthine and hypoxanthine, the final 
oxidation product of purine metabolism and is excreted in urine. 
Orfao et al 1989 analysed 62 previously untreated patients with CLL and significantly 
reduced survival was observed in patients with elevated level of uric acid. This 
statement was supported by Lee et al 1987. In his analysis a strong correlation 
between uric acid level and survival was demonstrated. Also, Prokocimer et al 1985, 
who analysed 90 patients with CLL, found significant correlation between 
hyperuricemia and survival.  Diverse to these analyses no significant difference was 
seen in both progression free survival (P value 0.205) and overall survival (P value 
0.428).  
4.11 Serum creatinine 
Creatinine is a break-down product of creatine phosphate in muscle, and is usually 
produced at a fairly constant rate by the body. Measuring serum creatinine is a 
simple test and it is the most commonly used indicator of renal function.  
After analysing 154 patients for 5 years Hallek et al 1996 found no significant 
correlation between serum creatinine and progression free survival. Unlike that Lee 
et al 1987 found a significant strong correlation between serum creatinine and overall 
survival. In this study significant difference (P value < 0.01) was shown concerning 
both progression free survival and overall survival. This supports also the statement 
of Lee et al 1987 but not the one of Hallek et al 1996. This might be, because first: 
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Hallek analysed not only chronic lymphocytic leukemia patients but also patients with 
lymphoplasmacytic lymphomas, second: several patients had already been  treated 
in other studies.  
4.12  Total bilirubin 
Bilirubin (formerly referred to as hematoidin) is the yellow breakdown product of 
normal heme catabolism. Heme is found in hemoglobin, a principal component of red 
blood cells. Bilirubin is created by the activity of biliverdin reductase on biliverdin, a 
green tetrapyrrolic bile pigment which is also a product of heme catabolism. 
After analysing 325 previously untreated patients with CLL to identify significant 
prognostic factors for survival Lee et al 1987 found no significant correlation between 
overall survival and serum bilirubin levels. Alike the analysis above, in this study no 
significant correlation between total bilirubin and either progression free survival or 
overall survival was proven.   
4.13  Hepatomegaly 
Since the liver is a lymphatic tissue, patients with advanced stage of lymphoid 
malignancies often present with an enlarged liver, so called hepatomegaly. We 
analyse in this study the prognostic value of clinical or palpable hepatomegaly 
concerning both progression free survival and overall survival. 
The analysis concerning progression free survival in this study shows no significant 
difference between patients with or without hepatomegaly (P value 0.220). Günther 
et al 2008 found also no significant correlation between hepatomegaly and 
progression free survival.   
There are already several studies about prognostic factors for CLL patients. Lee et al 
1987 analysed significant difference in terms of overall survival between patients with 
and without hepatomegaly.  Orfao et al 1989 identified hepatomegaly as being 
associated with survival. In his study (Prockocimer et al 1985) a significant 
correlation between hepatomegaly and survival is shown. Pines et al 1987 found, 
that hepatomegaly was associated with shorter survival. In contrast to this analysis, 
the current study shows with P value 0.621 actually no significant association 
between overall survival and hepatomegaly. The different result in this study could be 
because of the possibility that the patients in the referred studies were in higher 
advanced stages, related to a higher  mortality rate.  
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4.14 Splenomegaly 
Since the spleen is a lymphatic tissue, patients with advanced stage of lymphoid 
malignancies often present with splenomegaly.  There are several studies about 
prognostic value of splenomegaly in CLL patients. Günther et al 2008 could not prove 
significant correlation between splenomegaly and progression free survival. Unlike 
that, with a P value of 0.006 we can see a significant difference between patients 
with and without in terms of progression free survival.  
Similar results as hepatomegaly can also be found concerning splenomegaly. Many 
authors analysed, that there was significant influence of splenomegaly on overall 
survival (Lee et al 1987, Orfao et al 1989, Prokocimer et al 1985).  Against this 
analysis, Pines et al 1987 could not prove significant influence of splenomegaly on 
survival. Also in this study, no significant relationship between palpable 
splenomegaly and overall survival was demonstrated.   
4.15 Lymphadenopathy 
The early symptoms and signs of CLL include fatigue, reduced exercise tolerance, 
enlarged lymph nodes, and splenomegaly or hepatomegaly. Within this analysis an 
enlarged lymph node had to have a diameter of at least 1.5 cm. We analysed in this 
study the relevance of lymphadenopathy to survival in several lymph node areas, 
namely axillary, cervical, and inguinal. In terms of progression free survival, we found 
significant correlation between progression free survival and lymphadenopathy in 
axillary and cervical regions (P value for both < 0.001), whereas no significant 
correlation in inguinal area was demonstrated (P value 0.242). This analysis was 
supported by the analysis of Günther et al 2008. She also found significant 
correlation in both axillary and cervical regions, but not inguinal region.  
Lee et al 1987 analysed significant correlation between overall survival and 
lymphadenopathy in both external/peripheral and mediastinal regions. This statement 
could be supported by the analysis of Orfao et al 1989. He identified, that the 
presence of lymphadenopathies significantly influenced survival and were associated 
with a worse prognosis (Orfao et al 1989). Also Prokocimer et al 1985 showed 
significant correlation of lymphadenopathy with overall survival. Unlike that, Pines et 
al 1987 analysed no influence of the presence of lymphadenopathy on overall 
survival. We can see as well in this study, that there was no significant difference 
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concerning overall survival between CLL patients with and without  lymphadenopathy 
in axillary, cervical, inguinal region.     
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5 Conclusion 
The purpose of this study was to identify new prognostic factors for chronic 
lymphocytic leukemia patients concerning progression free survival and overall 
survival. We analysed CLL patients in early Binet stage A with both low risk and high 
risk for progression, but without treatment indication. High risk means not-nodular 
bone marrow infiltration or lymphocytes doubling time < 12 months and serum 
thymidine kinase > 7.0 U/l or serum- ß2-microglobulin > 3.5 mg/l. In summary of the 
analysis in this study in terms of progression free survival, six parameters (lactate 
dehydrogenase, blood urea nitrogen, serum creatinine, splenomegaly, axillary 
lymphadenopathy, cervical lymphadenopathy) significantly predicted progression free 
survival. Elevated lactate dehydrogenase level, blood urea nitrogen level, serum 
creatinine level and pathologic palpable splenomegaly, axillary lymphadenopathy and 
cervical lymphadenopathy were associated with poor prognosis. Only two 
parameters could predict significantly overall survival, namely blood urea nitrogen 
and serum creatinine. Elevated levels of blood urea nitrogen as well as elevated 
serum creatinine levels were associated with poorer prognosis. The other prognostic 
parameters (B-symptoms, ECOG general condition, alkaline phosphatase, serum 
glutamic oxalacetic transaminase, serum glutamate pyruvate transaminase, gamma-
glutamyltransferase, cholinesterase, uric acid, total bilirubin, hepatomegaly, inguinal 
lymphadenopathy) could not predict progression free survival nor overall survival.   
All estimated parameters are easily to assess and belong to a routine work-up of CLL 
patients. Before suggesting a prognostic score of all these analyzed parameters, they 
have to be analyzed together with modern parameters like cytogenetic and molecular 
genetic parameter after a longer follow-up period of the study population using a 
multivariate Cox regression model to prove their significance for prognosis prediction. 
Nevertheless, all these significant parameters for progression-free survival and 
overall survival in the univariate analysis are worthwhile to test in a multivariate 
analysis.     
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